$Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction$

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Abstract Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacub...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal 2021-09, Vol.42 (36), p.3741-3752
Hauptverfasser:	Jackson, Alice M, Jhund, Pardeep S, Anand, Inder S, Düngen, Hans-Dirk, Lam, Carolyn S P, Lefkowitz, Marty P, Linssen, Gerard, Lund, Lars H, Maggioni, Aldo P, Pfeffer, Marc A, Rouleau, Jean L, Saraiva, Jose F K, Senni, Michele, Vardeny, Orly, Wijkman, Magnus O, Yilmaz, Mehmet B, Saito, Yoshihiko, Zile, Michael R, Solomon, Scott D, McMurray, John J V
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminobutyrates - therapeutic use Angiotensin Receptor Antagonists - therapeutic use Biphenyl Compounds Clinical Research Double-Blind Method Drug Combinations Heart Failure - complications Heart Failure - drug therapy Humans Hypertension - complications Hypertension - drug therapy Neprilysin Stroke Volume Tetrazoles - therapeutic use Treatment Outcome Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!